BruxismNCT00807430
Treatment Period and Long-term Effect of Functional Electric Stimulation (FES) for Bruxism
A study testing Grindcare (Active) in people with Bruxism, run by Medotech A/S at 1 site in Denmark.
Trial summary
To investigate the effect of the treatment with Grindcare® on the muscles- and jaw symptoms and at the jaw muscle activity during sleep. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bruxism
- What is being tested?
- Grindcare (Active)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 1 siteDenmark
- Study dates
- Feb 2009to Oct 2009
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed and dated ICF
- 18 years or older
- Fulfill the RDC-criteria for myofascial TMD diagnose (group 1a or 1b)
- Average pain more that 3 on a Visual Analog scale (VAS) in the baseline period
Who cannot join
- Contraindication of concommitant diseases for the study judged by investigator
- Daily use of pain medication, e.g. prophylaxis against migraine or headache.
- Patients who are using occlusal splints in the treatment period.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Bruxism
To investigate the effect of the treatment with Grindcare® on the muscles- and jaw symptoms and at the jaw muscle activity during sleep.
- Conditions
- Bruxism
- Being tested
- Grindcare (Active), Grindcare (Placebo - the device is not activated)
- Keywords
- Bruxism, EMG, Biofeedback
- Medical subject headings
- Bruxism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Grindcare (Active)Device
Active treatment
Grindcare (Placebo - the device is not activated)Device
Placebo treatment
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | 24 patients receiving active treatment Receives: Device: Grindcare (Active) |
| 2 | Placebo comparator | Placebo treatment Receives: Device: Grindcare (Placebo - the device is not activated) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary outcome is to reduce the EMG activity per hour per night
Measured: 10 weeks after start of treatment
Secondary outcomes (1)
Secondary outcome is to evaluate long-term effect of FES om EMG activity
Measured: after end of treatment with FES
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2008 (estimated)
- Study startFeb 2009
- Primary completionJun 2009
- Study completionOct 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BruxismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medotech A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Troels B Mortensen, Study director, Medotech A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00807430
- Sponsor's protocol ID
- TMD-00
- Status last verified
- Oct 2009
- First submitted
- 9 Dec 2008
- Last updated
- 21 Oct 2009
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Bruxism
- ClinicalTrials.gov ID
- NCT00807430
- Acronym / sponsor ID
- TMD-00
- Conditions
- Bruxism
- Keywords
- Bruxism, EMG, Biofeedback
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Medotech A/SIndustry (pharma, biotech, devices)
- Study start
- Feb 2009
- Primary completion
- Jun 2009 (actual)
- Study completion
- Oct 2009 (actual)
- First posted
- 11 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the effect of the treatment with Grindcare® on the muscles- and jaw symptoms and at the jaw muscle activity during sleep.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Device: Grindcare (Active)24 patients receiving active treatment |
| 2 | Placebo comparator | Device: Grindcare (Placebo - the device is not activated)Placebo treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Signed and dated ICF
- 18 years or older
- Fulfill the RDC-criteria for myofascial TMD diagnose (group 1a or 1b)
- Average pain more that 3 on a Visual Analog scale (VAS) in the baseline period
Key exclusion criteria (3 listed)
- Contraindication of concommitant diseases for the study judged by investigator
- Daily use of pain medication, e.g. prophylaxis against migraine or headache.
- Patients who are using occlusal splints in the treatment period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Grindcare (Active)Active treatment | Device | 1 |
| Grindcare (Placebo - the device is not activated)Placebo treatment | Device | 2 |
Primary outcome
Primary outcome is to reduce the EMG activity per hour per night
Time frame: 10 weeks after start of treatment
1 secondary outcome
Secondary outcome is to evaluate long-term effect of FES om EMG activity
Time frame: after end of treatment with FES
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2009.
Related trials for Bruxism
RecruitingObservational study
Bruxism, Anxiety, and Periodontal Status Among Dental Students
Bruxism, Anxiety
RecruitingObservational study
Movement of Dental Implants During Osseointegration
Dental Implants, Osseointegration
Enrolling by invitationObservational study
The General Aim is to Implement Clinical Assessment of Overload by Voluntary Bite Force Registration to Enable Future Simple But Precise Risk Assessment to Provide Individualized Treatment Plans.
Dental Implant, Bruxism
RecruitingObservational study
Effect Of Orofacial Pain Therapy On Bruxism
Masticatory Myofascial Pain
Not yet recruiting
Influence Of Different Relaxation Techniques On Stress Level For Patients With Bruxism Using Salivary Biomarkers.
Bruxism, Stress (Psychology)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Troels B Mortensen study director
Medotech A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Grindcare (Active) in people with Bruxism, run by Medotech A/S at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 21 Oct 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary outcome is to reduce the EMG activity per hour per night (time frame: 10 weeks after start of treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2009.